Drug testing in Europe: monitoring results of the Trans European Drug Information (TEDI) project

Abstract

Drug testing is a harm reduction strategy that has been adopted by certain countries in Europe. Drug users are able to hand in their drugs voluntarily for chemical analysis of composition and dose. Drug users will be alerted about dangerous test results by the drug testing systems directly and through warning campaigns. An international collaborative effort was launched to combine data of drug testing systems, called the Trans European Drug Information (TEDI) project. Drug testing systems of Spain, Switzerland, Belgium, Austria, Portugal, and the Netherlands participated in this project. This study presents results of some of the main illicit drugs encountered: cocaine, ecstasy and amphetamine and also comments on new psychoactive substances (NPS) detected between 2008 and 2013. A total of 45 859 different drug samples were analyzed by TEDI. The drug markets of the distinct European areas showed similarities, but also some interesting differences. For instance, purity of cocaine and amphetamine powders was generally low in Austria, whilst high in Spain and the Netherlands. And the market for ecstasy showed a contrast: whereas in the Netherlands and Switzerland there was predominantly a market for ecstasy tablets, in Portugal and Spain MDMA (3,4-methylenedioxymethamphetamine) crystals were much more prevalent. Also, some NPS appearing in ecstasy seemed more specific for one country than another. In general, prevalence of NPS clearly increased between 2008 and 2013. Drug testing can be used to generate a global picture of drug markets and provides information about the pharmacological contents of drugs for the population at risk. Copyright © 2016 John Wiley & Sons, Ltd.

Consumption Patterns of Nightlife Attendees in Munich: A Latent-Class Analysis

“…This method has found great approval in countries where this is possible (Brunt et al, 2017;Hungerbuehler, Buecheli, & Schaub, 2011;Wiese & Verthein, 2014) as it provides a further opportunity of educating the consumer on the harms and risks of the substance they are to ingest. However, these tests are not legally possible in Germany.…”

Fentanyl in the US heroin supply: A rapidly changing risk environment

“…Carroll et al and Ciccarone et al discuss the effect that controlled consumption of drug, aka a “tester shot”, “taste” or insufflation (aka snorting) prior to or in lieu of injection might have in reducing overdose risk (Carroll et al 2017, Ciccarone, Ondocsin, and Mars 2017). Point-of-use testing or “drug checking” has been used especially in Europe, to inform and engage persons who consume drugs as well as provide a potential surveillance platform (Hondebrink et al 2015, Caudevilla et al 2016, Brunt et al 2017). Rapid testing exists for some of the fentanyls and several contributors point out the positives and the challenges of this harm reduction strategy (Ciccarone, Ondocsin, and Mars 2017, Nadia, Coffin, and Walley 2017, Gilbert and Dasgupta 2017).…”

Naloxone for heroin, prescription opioid, and illicitly made fentanyl overdoses: Challenges and innovations responding to a dynamic epidemic

“…One such strategy includes drug checking facilities, common in Europe, particularly among people who use ecstasy and stimulants, that allow people who use drugs to check for presence of illicit opioids prior to use and bridges to low barrier access to harm reduction and other services (Brunt et al, 2017; Caudevilla et al, 2016). Drug checking has existed since at least the beginning of the 21 st century (“EcstasyData,” 2017), but there is an increased interest in the context of overdose prevention, including the recent announcement of the first International Drug Checking Day on May 31 st , 2017 (“Drug Checking Day,” 2017).…”